BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 15642906)

  • 21. Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group (TROG).
    O'Brien PC; Roos DE; Liew KH; Trotter GE; Barton MB; Walker QJ; Poulsen MG; Olver IN
    Med J Aust; 1996 Oct; 165(8):424-7. PubMed ID: 8913243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system.
    Illerhaus G; Müller F; Feuerhake F; Schäfer AO; Ostertag C; Finke J
    Haematologica; 2008 Jan; 93(1):147-8. PubMed ID: 18166803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.
    Ekenel M; Iwamoto FM; Ben-Porat LS; Panageas KS; Yahalom J; DeAngelis LM; Abrey LE
    Cancer; 2008 Sep; 113(5):1025-31. PubMed ID: 18618509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [High-dose methotrexate followed by whole-brain irradiation for primary central nervous system lymphoma patients--a retrospective study in a single institute].
    Usui N; Dobashi N; Yano S; Yahagi Y; Takei Y; Otsubo H; Takahara S; Yamaguchi Y; Saito T; Minami J; Kamiyama Y; Morikawa N; Machishima T; Osawa H; Aiba K
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1277-82. PubMed ID: 20647709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
    Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
    Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
    Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
    Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
    Shenkier TN; Voss N; Chhanabhai M; Fairey R; Gascoyne RD; Hoskins P; Klasa R; Morris J; O'Reilly SE; Pickles T; Sehn L; Connors JM
    Cancer; 2005 Mar; 103(5):1008-17. PubMed ID: 15651059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
    Soussain C; Hoang-Xuan K; Taillandier L; Fourme E; Choquet S; Witz F; Casasnovas O; Dupriez B; Souleau B; Taksin AL; Gisselbrecht C; Jaccard A; Omuro A; Sanson M; Janvier M; Kolb B; Zini JM; Leblond V;
    J Clin Oncol; 2008 May; 26(15):2512-8. PubMed ID: 18413641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma.
    Pöttgen C; Stuschke M; Stüben G; Schmitz A; Schwechheimer K; Wacker HH; Rauhut F; Kleuker S; Wilhelm H; Grehl S; Fehlings T
    Strahlenther Onkol; 2003 Sep; 179(9):626-32. PubMed ID: 14628129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
    Colombat P; Lemevel A; Bertrand P; Delwail V; Rachieru P; Brion A; Berthou C; Bay JO; Delepine R; Desablens B; Camilleri-Broët S; Linassier C; Lamy T
    Bone Marrow Transplant; 2006 Sep; 38(6):417-20. PubMed ID: 16951691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
    Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
    Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma.
    Hottinger AF; DeAngelis LM; Yahalom J; Abrey LE
    Neurology; 2007 Sep; 69(11):1178-82. PubMed ID: 17846417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
    Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
    Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy.
    Ferreri AJ; Verona C; Politi LS; Chiara A; Perna L; Villa E; Reni M
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):169-75. PubMed ID: 20584577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study.
    Fliessbach K; Helmstaedter C; Urbach H; Althaus A; Pels H; Linnebank M; Juergens A; Glasmacher A; Schmidt-Wolf IG; Klockgether T; Schlegel U
    Neurology; 2005 Apr; 64(7):1184-8. PubMed ID: 15824344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
    Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
    Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of primary central nervous system lymphoma in the immunocompetent patient].
    Sierra Del Rio M; Benouaich-Amiel A; Psimaras D; Dehais C; Hoang-Xuan K
    Rev Neurol (Paris); 2008; 164(6-7):569-74. PubMed ID: 18565356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
    Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M;
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary central nervous system lymphoma. Results at the University of California at Los Angeles and review of the literature.
    Selch MT; Shimizu KT; De Salles AF; Sutton C; Parker RG
    Am J Clin Oncol; 1994 Aug; 17(4):286-93. PubMed ID: 8048389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
    Ferreri AJ; Dell'Oro S; Foppoli M; Bernardi M; Brandes AA; Tosoni A; Montanari M; Balzarotti M; Spina M; Ilariucci F; Zaja F; Stelitano C; Bobbio F; Corazzelli G; Baldini L; Ponzoni M; Picozzi P; Caligaris Cappio F; Reni M
    Neurology; 2006 May; 66(9):1435-8. PubMed ID: 16682682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.